今日观察！A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.

魅族 20 Pro 再创新低：百亿补贴价仅 2339 元，限时抢购！

北京，中国 – 2024 年 6 月 14 日 – 备受关注的魅族 20 Pro 手机迎来了史低价格！今日，魅族官方宣布，魅族 20 Pro 百亿补贴价降至 2339 元，立减 1660 元，限时抢购！

魅族 20 Pro 是魅族于 2020 年推出的旗舰手机，搭载了高通骁龙 865 处理器、6.65 英寸 AMOLED 显示屏、索尼 IMX686 主摄像头等旗舰级配置。凭借出色的性能和拍照表现，该机上市后备受好评。

百亿补贴，钜惠不停

此次百亿补贴活动，魅族 20 Pro 8GB+256GB 版本售价直降至 2339 元，12GB+256GB 版本售价直降至 2639 元。相比原价，两款版本均大幅下调了价格，优惠力度空前。

性能强劲，拍照出色

魅族 20 Pro 拥有强悍的性能表现，可轻松满足日常使用和游戏需求。该机配备了高通骁龙 865 处理器，辅以 LPDDR5 内存和 UFS 3.0 闪存，性能强劲流畅。此外，该机还搭载了 Flyme 8 系统，为用户带来更加流畅、智能的使用体验。

在拍照方面，魅族 20 Pro 也表现出色。该机后置三摄模组，由 6400 万像素主摄像头、1600 万像素超广角镜头和 800 万像素长焦镜头组成，可满足不同场景的拍摄需求。其中，主摄像头采用索尼 IMX686 传感器，拥有 1/1.7 英寸大底，支持四合一像素融合技术，在暗光环境下也能拍摄出清晰明亮的照片。

限时抢购，不容错过

魅族 20 Pro 百亿补贴活动将于今日起正式开启，限时抢购！如此优惠的价格，相信很快就会被抢购一空。想要入手一款高性能、拍照出色的手机，千万不要错过这次机会！

魅族 20 Pro 百亿补贴价详情：

• 8GB+256GB 版本：原价 3999 元，百亿补贴价 2339 元，立减 1660 元
• 12GB+256GB 版本：原价 4499 元，百亿补贴价 2639 元，立减 1860 元